Evidence map›Paper›PMID 41206311›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2026

Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep.

Benjamin A Lear, Christopher A Lear, Simerdeep K Dhillon, Victoria J King, Justin M Dean, Joanne O Davidson, Alistair J Gunn, Laura Bennet

Abstract read
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Commentary on: "Delayed necrostatin-1s infusion attenuates cystic white matter injury in preterm fetal sheep."Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benjamin A LearThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Christopher A LearThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Simerdeep K DhillonThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Victoria J KingThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Justin M DeanThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Joanne O DavidsonThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Alistair J GunnThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand.
Laura BennetThe Fetal Physiology and Neuroscience Group, Department of Physiology, The University of Auckland, Auckland, New Zealand. Electronic address: l.bennet@auckland.ac.nz.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe, cystic white matter injury (WMI) in preterm infants is associated with neurodevelopmental impairment. Strikingly, it often develops weeks after birth. In the present study we tested the hypothesis that necrotic programmed cell death, necroptosis, may be a key mediator of severe WMI, using the specific inhibitor necrostatin-1s (Nec-1s). Chronically instrumented preterm fetal sheep (0.7 gestation) received 25 ​min of hypoxia-ischaemia induced by complete umbilical cord occlusion (UCO) or sham-UCO (controls, n ​= ​9), followed by intracerebroventricular infusion of Necrostatin-1s at 3, 8 and 13 days after UCO (UCO-Nec-1s, n ​= ​8) or vehicle (UCO-vehicle, n ​= ​9). Histology was obtained at 21 days after UCO. UCO-vehicle was associated with a spectrum of brain injury including diffuse WMI, and in 7/9 fetuses, generalised white matter atrophy, ventriculomegaly and/or temporal lobe cystic lesions. Necrostatin-1s infusion was associated with less severe WMI in the temporal lobe (1/8, p ​= ​0.041), with reduced atrophy, increased density of mature oligodendrocyte cells, myelin area fraction, and reduced microgliosis but increased numbers of apoptotic cells. Interestingly, diffuse white matter injury in the parietal tracts was not affected. This study suggests that delayed, severe white matter injury after acute hypoxia-ischaemia is mediated by slowly evolving necroptosis and neuroinflammation. We speculate that Nec-1s shifts the dominant cell death pathway from necrosis toward apoptosis, allowing reduced inflammation and so preserving oligodendrocyte populations and myelination in the temporal lobe. These results suggest that necroptosis is a promising therapeutic target to mitigate severe white matter injury.

Indexed as

ImidazolesIndolesNeuroprotective AgentsWhite MatterAnimalsBrainDisease Models, AnimalFemaleFetusHypoxia-Ischemia, BrainPregnancySheepImidazolesIndolesnecrostatin-1Neuroprotective AgentsHypoxia-ischaemiaNecrostatin-1sPeriventricular leucomalaciaPretermWhite matter injury

Identifiers

PMID41206311
PMCPMC12976477

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.